Study of Nurtec ODT for migraine after market release in Korea
Part of Brain & nervous system, Pain clinical trials.
This study looks at how Nurtec ODT 75 mg works in real life for people in Korea who take it for migraines. It helps gather more information about the medicine's effects outside of clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have taken Nurtec ODT 75 mg as prescribed by your doctor.
- You agree to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational tablet called BR005-036C for quickly treating migraine attacks in adults. If you have frequent migraines but not too many headache days overall, you might be able to join and help see if this new medicine is safe and effective.
This trial tests a new oral medication to treat migraine attacks in adults who get them regularly. It might reduce the number of attacks and improve your quality of life.
This study tests if the medicine rimegepant is safe for people with migraine. You may be able to join if you have had migraine for at least a year, have 4–14 migraine days per month, and have not had good results with other migraine medicines called triptans.
This trial tests two fast-dissolving migraine medicines, Nurtec ODT and Maxalt MLT-ODT, in adults coming to the emergency room with a migraine. The goal is to see which one works better and faster for pain relief.
This study tests a medicine called rimegepant to see if it helps prevent migraines. If you have migraine at least 4 days per month, this might be for you.
This study tests whether taking an additional dose of rimegepant (a migraine medicine you may already use) is safe and helpful for adults with migraine. Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist—a type of medicine that blocks a protein involved in migraine pain.
Hear when a new Migraine With or Without Aura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.